NASDAQ:SIGA Stock Quote
Siga Technologies Inc is a biotechnology company focused on developing solutions for public health threats, particularly through its innovative antiviral therapeutics
The company's primary emphasis is on the advancement of treatments for viral infections, with a notable concentration on smallpox and other serious infectious diseases. By leveraging its proprietary technologies, Siga aims to address unmet medical needs and improve health outcomes, especially in the face of potential bioterrorism threats or emerging viral outbreaks. Through collaborations with government entities and investment in research, the company endeavors to enhance global health security and preparedness through effective medical interventions.
Frequently Asked Questions
Has SIGA received government contracts?
Yes, SIGA Technologies has received substantial government contracts, particularly from the U.S. Department of Health and Human Services. These contracts are often aimed at stockpiling their antiviral drugs for national security and emergency preparedness.
How does SIGA Technologies contribute to global health?
SIGA Technologies contributes to global health by developing treatments for infectious diseases that pose a threat to public safety. Their technologies aim to enhance preparedness against potential outbreaks and improve response operations globally.
How does SIGA Technologies ensure product safety?
SIGA Technologies ensures product safety through rigorous clinical testing, adherence to regulatory guidelines established by health authorities like the FDA, and by conducting post-marketing surveillance once products are in the market.
How does SIGA Technologies handle regulatory compliance?
SIGA Technologies handles regulatory compliance by following stringent guidelines set by health authorities like the FDA. This involves standard procedures for clinical trials, manufacturing processes, and post-market monitoring to ensure all products meet safety and efficacy standards.
How does SIGA Technologies support biodefense?
SIGA Technologies supports biodefense by developing antiviral therapies like TPOXX, which are crucial for responding to potential biological threats. They provide the necessary tools for preparedness and response to outbreaks of diseases considered to be bioweapons.
Is SIGA Technologies publicly traded?
Yes, SIGA Technologies Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol 'SIGA'. Investors can buy and sell shares of the company just like any other publicly listed entity.
What are some risks associated with investing in SIGA Technologies?
Some risks associated with investing in SIGA Technologies include the potential volatility of biotech stocks, regulatory hurdles that can affect product approval, dependency on government contracts, and the ability to successfully innovate and commercialize new therapies.
What are the competitive advantages of SIGA Technologies?
SIGA Technologies' competitive advantages include its specialized focus on antiviral drugs for biodefense, strong intellectual property protections, established relationships with government agencies, and a robust research and development pipeline.
What are the future plans for SIGA Technologies?
SIGA Technologies plans to expand its product pipeline by developing new antiviral therapies and conducting ongoing research into emerging infectious diseases. The company also aims to enhance its biodefense capabilities through strategic partnerships and funding.
What are the key partnerships of SIGA Technologies?
SIGA Technologies has established various strategic partnerships with government agencies, research institutions, and pharmaceutical companies to further their research and development efforts. Notably, they have collaborated with the U.S. government and other entities for biodefense initiatives.
What clinical trials has SIGA conducted?
SIGA has conducted numerous clinical trials to evaluate the efficacy and safety of their antiviral products, particularly TPOXX, in treating smallpox and other orthopoxvirus infections. The results have supported their regulatory submissions and approvals.
What does SIGA Technologies Inc. do?
SIGA Technologies Inc. is a biotechnology company focused on developing and commercializing innovative solutions for public health emergencies, particularly related to biodefense and emerging infectious diseases. They are well-known for their work in developing antiviral therapeutics, especially for diseases caused by viral infections.
What is the financial performance of SIGA Technologies?
SIGA Technologies' financial performance can vary, but they have seen periods of growth largely attributed to their successful product sales, government contracts, and grants. Investors typically evaluate their financial health based on revenue, profit margins, research funding, and stock performance.
What is the primary product of SIGA?
The primary product of SIGA Technologies is TPOXX (tecovirimat), an antiviral drug that has been approved by the FDA for the treatment of smallpox. TPOXX is a critical tool in biodefense, providing a treatment option in the event of a smallpox outbreak.
What is the significance of TPOXX in healthcare?
TPOXX is significant in healthcare as it provides a proven antiviral treatment for smallpox, which is critical given the potential threat of bioterrorism. It also provides a model for developing antivirals for other viral threats.
What type of diseases does SIGA focus on?
SIGA primarily focuses on viral diseases, particularly those that could present a significant threat to public health such as smallpox, monkeypox, and other orthopoxvirus infections. They also look into potential treatments for emerging infectious diseases.
When was SIGA Technologies founded?
SIGA Technologies was founded in 1995 and has since focused on addressing public health threats through the development of antiviral therapies and other innovative solutions.
Where is SIGA Technologies located?
SIGA Technologies Inc. is headquartered in New York City, New York, with additional facilities for research and development focused on their antiviral drug programs.
Who are the executives of SIGA Technologies?
The executives at SIGA Technologies include a team of experienced professionals with backgrounds in biotechnology, pharmaceuticals, and public health. The leadership is focused on guiding the company's strategic vision and operational efforts.
What is the current price of SIGA Technologies Inc. - Common Stock?
The current price of SIGA Technologies Inc. - Common Stock is 5.370
When was SIGA Technologies Inc. - Common Stock last traded?
The last trade of SIGA Technologies Inc. - Common Stock was at 2:01 pm EDT on April 2nd, 2025
What is the market capitalization of SIGA Technologies Inc. - Common Stock?
The market capitalization of SIGA Technologies Inc. - Common Stock is 381.72M
How many shares of SIGA Technologies Inc. - Common Stock are outstanding?
SIGA Technologies Inc. - Common Stock has 71.08M shares outstanding.